Trajectories of complex neurocognitive phenotypes in preclinical aging may be produced differentially through selective and interactive combinations of genetic risk.
Objective:
We organize three possible combinations into a “network” of genetic risk indices derived from polymorphisms associated with normal and impaired cognitive aging, as well as Alzheimer’s disease (AD). Specifically, we assemble and examine three genetic clusters relevant to non-demented cognitive trajectories: 1) Apolipoprotein E (APOE), 2) a Cognitive Aging Genetic Risk Score (CA-GRS; Catechol-O-methyltransferase + Brain-derived neurotrophic factor), and 3) an AD-Genetic Risk Score (AD-GRS; Clusterin + Complement receptor 1 + Phosphatidylinositol-binding clathrin assembly protein).
Method:
We use an accelerated longitudinal design (n = 634; age range = 55–95 years) to test whether AD-GRS (low versus high) moderates the effect of increasing CA-GRS risk on executive function (EF) performance and change as stratified by APOE status (ɛ4+ versus ɛ4–).
Results:
APOEɛ4 carriers with high AD-GRS had poorer EF performance at the centering age (75 years) and steeper 9-year decline with increasing CA-GRS but this association was not present in APOEɛ4 carriers with low AD-GRS.
Conclusions:
APOEɛ4 carriers with high AD-GRS are at elevated risk of cognitive decline when they also possess higher CA-GRS risk. Genetic risk from both common cognitive aging and AD-related indices may interact in intensification networks to differentially predict (1) level and trajectories of EF decline and (2) potential selective vulnerability for transitions into impairment and dementia.
BarnesDE, YaffeK (2011) The projected effect of risk factor reduction on Alzheimer’s disease prevalence. Lancet Neurol10, 819–828.
2.
BrookmeyerR, JohnsonE, Ziegler-GrahamK, ArrighiHM (2007) Forecasting the global burden of Alzheimer’s disease. Alzheimers Dement3, 186–191.
3.
HoltzmanDM, MorrisJC, GoateAM (2011) Alzheimer’s disease: The challenge of the second century. Sci Transl Med3, 77sr1–77sr1.
4.
SperlingRA, AisenPS, BeckettLA, BennettDA, CraftS, FaganAM, IwatsuboT, JackCR, KayeJ, MontineTJ, ParkDC, ReimanEM, RoweCC, SiemersE, SternY, YaffeK, CarrilloMC, ThiesB, Morrison-BogoradM, WagsterMV, PhelpsCH (2011) Toward defining the preclinical stages of Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimers Dement7, 280–292.
5.
JackCR, KnopmanDS, JagustWJ, PetersenRC, WeinerMW, AisenPS, ShawLM, VemuriP, WisteHJ, WeigandSD, LesnickTG, PankratzVS, DonohueMC, TrojanowskiJQ (2013) Update on hypothetical model of Alzheimer’s disease biomarkers. Lancet Neurol12, 207–216.
6.
AllainP, Etcharry-BouyxF, VernyC (2013) Executive functions in clinical and preclinical Alzheimer’s disease. Rev Neurol (Paris)169, 695–708.
GatzM, ReynoldsCA, FratiglioniL, JohanssonB, MortimerJA, BergS, FiskeA, PedersenNL (2006) Role of genes and environments for explaining Alzheimer disease. Arch Gen Psychiatry63, 168.
McFallGP, SapkotaS, McDermottKL, DixonRA (2016) Risk-reducing Apolipoprotein E and Clusterin genotypes protect against the consequences of poor vascular health on executive function performance and change in nondemented older adults. Neurobiol Aging42, 91–100.
11.
SapkotaS, BäckmanL, DixonRA (2017) Executive function performance and change in aging is predicted by apolipoprotein E, intensified by catechol-O-methyltransferase and brain-derived neurotrophic factor, and moderated by age and lifestyle. Neurobiol Aging52, 81–89.
12.
GaiteriC, MostafaviS, HoneyCJ, De JagerPL, BennettDA (2016) Genetic variants in Alzheimer disease — molecular and brain network approaches. Nat Rev Neurol12, 413–427.
13.
BarabásiA-L, GulbahceN, LoscalzoJ (2011) Network medicine: A network-based approach to human disease. Nat Rev Genet12, 56–68.
14.
de FriasCM, DixonRA, StraussE (2006) Structure of four executive functioning tests in healthy older adults. Neuropsychology20, 206–214.
15.
LuszczM (2011) Executive function and cognitive aging. In Handbook of the psychology of aging,
SchaieK,
WillisS, eds. Elsevier, Inc, pp. 59–72.
16.
McFallGP, SapkotaS, ThibeauS, DixonRA (2017) Executive function in normal aging and neurodegenerative diseases: Trajectories and modifiers. In Executive Function: Development Across the Life Span,
WiebeSA,
KarbachJ, eds. Taylor & Francis, Oxford, UK pp. 296.
17.
LiuC-C, LiuC-C, KanekiyoT, XuH, BuG (2013) Apolipoprotein E and Alzheimer disease: Risk, mechanisms and therapy. Nat Rev Neurol9, 106–118.
18.
SaundersAM, StrittmatterWJ, SchmechelD, George-HyslopPH, Pericak-VanceMA, JooSH, RosiBL, GusellaJF, Crapper-MacLachlanDR, AlbertsMJ (1993) Association of apolipoprotein E allele epsilon 4 with late-onset familial and sporadic Alzheimer’s disease. Neurology43, 1467–1472.
19.
CorderEH, SaundersAM, StrittmatterWJ, SchmechelDE, GaskellPC, SmallGW, RosesAD, HainesJL, Pericak-VanceMA (1993) Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer’s disease in late onset families. Science261, 921–923.
20.
PoirierJ, DavignonJ, BouthillierD, KoganS, BertrandP, GauthierS (1993) Apolipoprotein E polymorphism and Alzheimer’s disease. Lancet342, 697–699.
LambertJ-C, HeathS, EvenG, CampionD, SleegersK, HiltunenM, CombarrosO, ZelenikaD, BullidoMJ, TavernierB, LetenneurL, BettensK, BerrC, PasquierF, FiévetN, Barberger-GateauP, EngelborghsS, De DeynP, MateoI, FranckA, HelisalmiS, PorcelliniE, HanonO, de PancorboMM, LendonC, DufouilC, JaillardC, LeveillardT, AlvarezV, BoscoP, MancusoM, PanzaF, NacmiasB, BossúP, PiccardiP, AnnoniG, SeripaD, GalimbertiD, HannequinD, LicastroF, SoininenH, RitchieK, BlanchéH, DartiguesJ-F, TzourioC, GutI, Van BroeckhovenC, AlpérovitchA, LathropM, AmouyelP (2009) Genome-wide association study identifies variants at CLU and CR1 associated with Alzheimer’s disease. Nat Genet41, 1094–1099.
23.
FarrerLA, CupplesLA, HainesJL, HymanB, KukullWA, MayeuxR, MyersRH, Pericak-VanceMA, RischN, van DuijnCM (1997) Effects of age, sex, and ethnicity on the association between apolipoprotein E genotype and Alzheimer disease. A meta-analysis. APOE and Alzheimer Disease Meta Analysis Consortium. JAMA278, 1349–1356.
24.
CaselliRJ, DueckAC, LockeDEC, Hoffman-SnyderCR, WoodruffBK, RapcsakSZ, ReimanEM (2011) Longitudinal modeling of frontal cognition in APOE ɛ4 homozygotes, heterozygotes, and noncarriers. Neurology76, 1383–1388.
25.
VivotA, GlymourMM, TzourioC, AmouyelP, ChêneG, DufouilC (2015) Association of Alzheimer’s related genotypes with cognitive decline in multiple domains: Results from the Three-City Dijon study. Mol Psychiatry20, 1173–1178.
26.
BertramL, TanziRE (2009) Genome-wide association studies in Alzheimer’s disease. Hum Mol Genet18, R137–1345.
27.
CarrasquilloMM, BelbinO, HunterTA, MaL, BisceglioGD, ZouF, CrookJE, PankratzVS, DicksonDW, Graff-RadfordNR, PetersenRC, MorganK, YounkinSG (2010) Replication of CLU, CR1, and PICALM associations with Alzheimer disease. Arch Neurol67, 2687–2702.
28.
CorneveauxJJ, MyersAJ, AllenAN, PruzinJJ, RamirezM, EngelA, NallsMA, ChenK, LeeW, ChewningK, VillaSE, MeechoovetHB, GerberJD, FrostD, BensonHL, O’ReillyS, ChibnikLB, ShulmanJM, SingletonAB, CraigDW, Van Keuren-JensenKR, DunckleyT, BennettDA, De JagerPL, HewardC, HardyJ, ReimanEM, HuentelmanMJ (2010) Association of CR1, CLU and PICALM with Alzheimer’s disease in a cohort of clinically characterized and neuropathologically verified individuals. Hum Mol Genet19, 3295–3301.
29.
ChenLH, Ping KaoPY, FanYH, Yin HoDT, ChanSY, YipPY, Tung HaJC, ChuLW, SongYQ (2011) Polymorphisms of CR1, CLU and PICALM confer susceptibility of Alzheimer’s disease in Southern Chinese population. Alzheimers Dement7, S181.
30.
KarchCM, GoateAM (2015) Alzheimer’s disease risk genes and mechanisms of disease pathogenesis. Biol Psychiatry77, 43–51.
31.
CaleroM, RostagnoA, MatsubaraE, ZlokovicB, FrangioneB, GhisoJ (2000) Apolipoprotein J (clusterin) and Alzheimer’s disease. Microsc Res Tech50, 305–315.
32.
BertramL, McQueenMB, MullinK, BlackerD, TanziRE (2007) Systematic meta-analyses of Alzheimer disease genetic association studies: The AlzGene database. Nat Genet39, 17–23.
33.
BraskieMN, JahanshadN, SteinJL, BaryshevaM, McMahonKL, de ZubicarayGI, MartinNG, WrightMJ, RingmanJM, TogaAW, ThompsonPM (2011) Common Alzheimer’s disease risk variant within the CLU gene affects white matter microstructure in young adults. J Neurosci31, 6764–6770.
SapkotaS, WiebeSA, SmallBJ, DixonRA (2016) Apolipoprotein E and Clusterin can magnify effects of personality vulnerability on declarative memory performance in non-demented older adults. Int J Geriatr Psychiatry31, 502–509.
XiaoQ, GilS-C, YanP, WangY, HanS, GonzalesE, PerezR, CirritoJR, LeeJ-M (2012) Role of phosphatidylinositol clathrin assembly lymphoid-myeloid leukemia (PICALM) in intracellular amyloid precursor protein (APP) processing and amyloid plaque pathogenesis. J Biol Chem287, 21279–21289.
39.
SchjeideB-MM, SchnackC, LambertJ-C, LillCM, KirchheinerJ, TumaniH, OttoM, TanziRE, LehrachH, AmouyelP, von ArnimCAF, BertramL (2011) The role of clusterin, complement receptor 1, and phosphatidylinositol binding clathrin assembly protein in Alzheimer disease risk and cerebrospinal fluid biomarker levels. Arch Gen Psychiatry68, 207.
40.
MorgenK, RamirezA, FrölichL, TostH, PlichtaMM, KölschH, RakebrandtF, RienhoffO, JessenF, PetersO, JahnH, LuckhausC, HüllM, GertzH, SchröderJ, HampelH, TeipelSJ, PantelJ, HeuserI, WiltfangJ, RütherE, KornhuberJ, MaierW, Meyer-LindenbergA (2014) Genetic interaction of PICALM and APOE is associated with brain atrophy and cognitive impairment in Alzheimer’s disease. Alzheimers Dement10, 1–8.
41.
BarralS, BirdT, GoateA, FarlowMR, Diaz-ArrastiaR, BennettDA, Graff-RadfordN, BoeveBF, SweetRA, SternY, WilsonRS, ForoudT, OttJ, MayeuxR (2012) Genotype patterns at PICALM, CR1, BIN1, CLU, and APOE genes are associated with episodic memory. Neurology78, 1464–1471.
42.
ThambisettyM, AnY, NallsM, SojkovaJ, SwaminathanS, ZhouY, SingletonAB, WongDF, FerrucciL, SaykinAJ, ResnickSM (2013) Effect of complement CR1 on brain amyloid burden during aging and its modification by APOE genotype. Biol Psychiatry73, 422–428.
43.
ChibnikLB, ShulmanJM, LeurgansSE, SchneiderJA, WilsonRS, TranD, AubinC, BuchmanAS, HewardCB, MyersAJ, HardyJA, HuentelmanMJ, CorneveauxJJ, ReimanEM, EvansDA, BennettDA, De JagerPL (2011) CR1 is associated with amyloid plaque burden and age-related cognitive decline. Ann Neurol69, 560–569.
44.
HarrisSE, DearyIJ (2011) The genetics of cognitive ability and cognitive ageing in healthy older people. Trends Cogn Sci15, 388–394.
45.
MandelmanSD, GrigorenkoEL (2012) BDNF Val66Met and cognition: All, none, or some? A meta-analysis of the genetic association. Genes Brain Behav11, 127–136.
46.
NagelIE, ChicherioC, LiS-C, von OertzenT, SanderT, VillringerA, HeekerenHR, BäckmanL, LindenbergerU (2008) Human aging magnifies genetic effects on executive functioning and working memory. Front Hum Neurosci2, 1.
47.
BilderRM, VolavkaJ, LachmanHM, GraceAA (2004) The catechol-O-methyltransferase polymorphism: Relations to the tonic-phasic dopamine hypothesis and neuropsychiatric phenotypes. Neuropsychopharmacology29, 1943–1961.
48.
SavitzJ, SolmsM, RamesarR (2006) The molecular genetics of cognition: Dopamine, COMT and BDNF. Genes Brain Behav5, 311–328.
49.
SapkotaS, VergoteD, WestawayD, JhamandasJ, DixonRA (2015) Synergistic associations of catechol-O-methyltransferase and brain-derived neurotrophic factor with executive function in agingare selective and modified by apolipoprotein E. Neurobiol Aging36, 249–256.
50.
HuY, XinJ, HuY, ZhangL, WangJ (2017) Analyzing the genes related to Alzheimer’s disease via a network and pathway-based approach. Alzheimers Res Ther9, 29.
SongA, YanJ, KimS, RisacherSL, WongAK, SaykinAJ, ShenL, GreeneCS (2016) Network-based analysis of genetic variants associated with hippocampal volume in Alzheimer’s disease: A study of ADNI cohorts. BioData Min9, 3.
ChourakiV, ReitzC, MauryF, BisJC, BellenguezC, YuL, JakobsdottirJ, MukherjeeS, AdamsHH, ChoiSH, LarsonEB, FitzpatrickA, UitterlindenAG, de JagerPL, HofmanA, GudnasonV, VardarajanB, Ibrahim-VerbaasC, van der LeeSJ, LopezO, DartiguesJ-F, BerrC, AmouyelP, BennettDA, van DuijnC, DeStefanoAL, LaunerLJ, IkramMA, CranePK, LambertJ-C, MayeuxR, SeshadriS, International Genomics of Alzheimer’s Project (2016) Evaluation of a genetic risk score to improve risk prediction for Alzheimer’s disease. J Alzheimers Dis53, 921–932.
57.
LacourA, EspinosaA, LouwersheimerE, HeilmannS, HernándezI, WolfsgruberS, FernándezV, WagnerH, Rosende-RocaM, MauleónA, Moreno-GrauS, VargasL, PijnenburgYAL, KoeneT, Rodríguez-GómezO, OrtegaG, RuizS, HolstegeH, Sotolongo-GrauO, KornhuberJ, PetersO, FrölichL, HüllM, RütherE, WiltfangJ, SchererM, Riedel-HellerS, AlegretM, NöthenMM, ScheltensP, WagnerM, TárragaL, JessenF, BoadaM, MaierW, van der FlierWM, BeckerT, RamirezA, RuizA (2017) Genome-wide significant risk factors for Alzheimer’s disease: Role in progression to dementia due to Alzheimer’s disease among subjects with mild cognitive impairment. Mol Psychiatry22, 153–160.
58.
AdamsHHH, de BruijnRFAG, HofmanA, UitterlindenAG, van DuijnCM, VernooijMW, KoudstaalPJ, IkramMA (2015) Genetic risk of neurodegenerative diseases is associated with mild cognitive impairment and conversion to dementia. Alzheimers Dement11, 1277–1285.
59.
SleegersK, BettensK, De RoeckA, Van CauwenbergheC, CuyversE, VerheijenJ, StruyfsH, Van DongenJ, VermeulenS, EngelborghsS, VandenbulckeM, VandenbergheR, De DeynPP, Van BroeckhovenC (2015) A 22-single nucleotide polymorphism Alzheimer’s disease risk score correlates with family history, onset age, and cerebrospinal fluid Aβ42. Alzheimers Dement11, 1452–1460.
60.
AndrewsSJ, EramudugollaR, VelezJI, CherbuinN, EastealS, AnsteyKJ (2017) Validating the role of the Australian National University Alzheimer’s Disease Risk Index (ANU-ADRI) and a genetic risk score in progression to cognitive impairment in a population-based cohort of older adults followed for 12 years. Alzheimers Res Ther9, 16.
MarioniRE, CampbellA, HagenaarsSP, NagyR, AmadorC, HaywardC, PorteousDJ, VisscherPM, DearyIJ (2017) Genetic stratification to identify risk groups for Alzheimer’s disease. J Alzheimers Dis57, 275–283.
63.
FerenczB, LaukkaEJ, WelmerA-K, KalpouzosG, AnglemanS, KellerL, GraffC, LövdénM, BäckmanL (2014) The benefits of staying active in old age: Physical activity counteracts the negative influence of PICALM, BIN1, and CLU risk alleles on episodic memory functioning. Psychol Aging29, 440–449.
64.
DixonRA, FriasCM De (2004) The Victoria Longitudinal Study: From characterizing cognitive aging to illustrating changes in memory compensation. Aging Neuropsychol Cogn11, 346–376.
65.
BielakAAM, MansuetiL, StraussE, DixonRA (2006) Performance on the Hayling and Brixton tests in older adults: Norms and correlates. Arch Clin Neuropsychol21, 141–149.
66.
McFallGP, WiebeSA, VergoteD, JhamandasJ, WestawayD, DixonRA (2014) IDE (rs6583817) polymorphism and pulse pressure are independently and interactively associated with level and change in executive function in older adults. Psychol Aging29, 418–430.
67.
BurgessP, ShalliceT (1997) The Hayling and Brixton Tests. Thames Val. Test Company, Bury St. Edmunds, U.K.
68.
TaylorSF, KornblumS, LauberEJ, MinoshimaS, KoeppeRA (1997) Isolation of specific interference processing in the Stroop task: PET activation studies. Neuroimage6, 81–92.
69.
D’eliaL, SatzP, UchiyamaC, UchiyamaC, WhiteT (1996) Color Trails Test Professional Manual, Psychological Assessment Resources, Florida.
70.
MuthénL, MuthénB (1998) Mplus user’s guide. Seventh edition., Muthén, L Muthén, B, Los Angeles, CA.
71.
SmallBJ, DixonRA, McArdleJJ (2011) Tracking cognition-health changes from 55 to 95 years of age. J Gerontol B Psychol Sci Soc Sci66B, i153–i161.
72.
HarrisonTM, MahmoodZ, LauEP, KaracozoffAM, BurggrenAC, SmallGW, BookheimerSY (2016) An Alzheimer’s disease genetic risk score predicts longitudinal thinning of hippocampal complex subregions in healthy older adults. eNeuro3, pii: ENEURO.0098-16.2016.
73.
AltmannA, TianL, HendersonVW, GreiciusMD (2014) Sex modifies the APOE-related risk of developing Alzheimer disease. Ann Neurol75, 563–573.
74.
KlineRB (2010), Principles and practice of structural equation modeling, Guilford Press, New York.
75.
AlexanderGE, DeLongMR, StrickPL (1986) Parallel organization of functionally segregated circuits linking basal ganglia and cortex. Annu Rev Neurosci9, 357–381.
76.
FerrariR, MorenoJH, MinhajuddinAT, O’BryantSE, ReischJS, BarberRC, MomeniP (2012) Implication of common and disease specific variants in CLU, CR1, and PICALM. Neurobiol Aging33, 1846.e7–1846.e18.
77.
YuJ-T, TanL (2012) The role of clusterin in Alzheimer’s disease: Pathways, pathogenesis, and therapy. Mol Neurobiol45, 314–326.
78.
BertrandP, PoirierJ, OdaT, FinchCE, PasinettiGM (1995) Association of apolipoprotein E genotype with brain levels of apolipoprotein E and apolipoprotein J (clusterin) in Alzheimer disease. Mol Brain Res33, 174–178.
79.
KimJ, BasakJM, HoltzmanDM (2009) The role of Apolipoprotein E in Alzheimer’s disease. Neuron63, 287–303.
80.
KennedyRE, CutterGR, SchneiderLS (2014) Effect of APOE genotype status on targeted clinical trials outcomes and efficiency in dementia and mild cognitive impairment resulting from Alzheimer’s disease. Alzheimers Dement10, 349–359.
81.
EndersCK (2011) Analyzing longitudinal data with missing values. Rehabil Psychol56, 267–288.
82.
KoranMEI, WagenerM, HohmanTJ (2017) Sex differences in the association between AD biomarkers and cognitive decline. Brain Imaging Behav11, 205–213.
